, Volume 235, Issue 8, pp 2377–2385 | Cite as

Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice

  • Jing Shi
  • Huaxia Liu
  • Jianchun Pan
  • Jie Chen
  • Nianping Zhang
  • Kaiping Liu
  • Ning Fei
  • James M. O’Donnell
  • Han-Ting ZhangEmail author
  • Ying XuEmail author
Original Investigation



Alcohol use disorder (AUD) is a chronically relapsing condition, which affects nearly 11% of population worldwide. Currently, there are only three FDA-approved medications for treatment of AUD, and normally, satisfactory effects are hard to be achieved. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling has been implicated in regulation of ethanol intake. Phosphodiesterase 2 (PDE), a dual substrate PDE that hydrolyzes both cAMP and cGMP, may play a crucial role in regulating ethanol consumption.


The present study determined whether PDE2 was involved in the regulation of ethanol intake and preference. The two-bottle choice procedure was used to examine the effects of the selective PDE2 inhibitor Bay 60-7550 on ethanol intake. The sucrose and quinine intake (taste preference) and locomotor activity (sedative effects) were also measured to exclude the false positive effects of Bay 60-7550.


Treatment with Bay 60-7550 (1 and 3 mg/kg, i.p.) decreased ethanol intake and preference, without changing total fluid intake. In addition, Bay 60-7550 at doses that reduced ethanol intake did not affect sucrose and quinine intake and preference, which excluded the potential influence of taste preference and sedative effects on ethanol drinking behavior. Moreover, Bay 60-7550 at 3 mg/kg did not alter locomotor activity or ethanol metabolism, further supporting the specific effect of Bay 60-7550 on ethanol drinking behavior.


The results suggest that PDE2 plays a role in the regulation of ethanol consumption and that PDE2 inhibitors may be a novel class of drugs for treatment of alcoholism.


PDE2 Bay 60-7550 cAMP/cGMP Ethanol intake Two-bottle choice 



This work was supported by research grants from NIH/NIAAA (HHSN275201700001C to H.-T. Zhang), National Nature Science Foundation of China (81773717 to H.-T. Zhang), and the Foundation of Overseas Distinguished Taishan Scholars of Shandong Province, China (to H.-T. Zhang). This work was also supported by The “13th Five-Year” Chinese Medicine Key Discipline in Zhejiang Province-Chinese Medicine Quality and functional evaluation (2017-XK-A43 to J. Shi).


  1. Alberini CM (2009) Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 89:121–145CrossRefPubMedGoogle Scholar
  2. Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, Becker HC (2015) Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol 20:38–42CrossRefPubMedGoogle Scholar
  3. Blednov YA, Benavidez JM, Black M, Harris RA (2014) Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci 27(8):129. CrossRefGoogle Scholar
  4. Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28:436–445CrossRefPubMedGoogle Scholar
  5. Carnicella S, Ron D, Barak S (2014) Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol 48:243–252CrossRefPubMedPubMedCentralGoogle Scholar
  6. Deng C, Wang D, Bugaj-Gaweda B, De Vivo M (2007) Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). Curr Protoc Neurosci. Chapter 7:Unit 7.21. doi:
  7. Ding L, Zhang C, Masood A, Li J, Sun J, Nadeem A, Zhang HT, JM OD, Xu Y (2014) Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res 268:150–158CrossRefPubMedPubMedCentralGoogle Scholar
  8. Driessen M, Schulte S, Luedecke C, Schaefer I, Sutmann F, Ohlmeier M, Kemper U, Koesters G, Chodzinski C, Schneider U, Broese T, Dette C, Havemann-Reinecke U, Group TR-S (2008) Trauma and PTSD in patients with alcohol, drug, or dual dependence: a multi-center study. Alcohol Clin Exp Res 32:481–488CrossRefPubMedGoogle Scholar
  9. Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118–1127CrossRefPubMedGoogle Scholar
  10. Geerts H, Spiros A, Roberts P (2017) Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. Expert Rev Neurother 17:553–560CrossRefPubMedGoogle Scholar
  11. Gong MF, Wen RT, Xu Y, Pan JC, Fei N, Zhou YM, Xu JP, Liang JH, Zhang HT (2017) Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents. Psychopharmacology 234:3143–3151CrossRefPubMedGoogle Scholar
  12. Hu W, Lu T, Chen A, Huang Y, Hansen R, Chandler LJ, Zhang HT (2011) Inhibition of phosphodiesterase-4 decreases ethanol intake in mice. Psychopharmacology 218:331–339CrossRefPubMedPubMedCentralGoogle Scholar
  13. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35(1):217–238CrossRefPubMedGoogle Scholar
  14. Lai M, Zhu H, Sun A, Zhuang D, Fu D, Chen W, Zhang HT, Zhou W (2014) The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior induced by cues or heroin priming in rats. Int J Neuropsychopharmacol 17:1397–1407CrossRefPubMedGoogle Scholar
  15. Liu X, Hao P-D, Yang M-F, Sun J-Y, Mao L-L, Fan C-D, Zhang Z-Y, Li D-W, Yang X-Y, Sun B-L, Zhang H-T (2017) The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice. Psychopharmacology 234:2409–2419CrossRefPubMedGoogle Scholar
  16. Logrip ML (2015) Phosphodiesterase regulation of alcohol drinking in rodents. Alcohol 49:795–802CrossRefPubMedPubMedCentralGoogle Scholar
  17. Logrip ML, Zorrilla EP (2012) Stress history increases alcohol intake in relapse: relation to phosphodiesterase 10A. Addict Biol 17:920–933CrossRefPubMedPubMedCentralGoogle Scholar
  18. Logrip ML, Zorrilla EP (2014) Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. Front Integr Neurosci 8(30).
  19. Logrip ML, Vendruscolo LF, Schlosburg JE, Koob GF, Zorrilla EP (2014) Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology 39(7):1722–1731CrossRefPubMedPubMedCentralGoogle Scholar
  20. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234:109–117CrossRefPubMedGoogle Scholar
  21. Masood A, Nadeem A, Mustafa SJ, O'Donnell JM (2008) Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J Pharmacol Exp Ther 326:369–379CrossRefPubMedPubMedCentralGoogle Scholar
  22. Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG, O'Donnell JM (2009) Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 331:690–699CrossRefPubMedPubMedCentralGoogle Scholar
  23. McPherson CS, Lawrence AJ (2007) The nuclear transcription factor CREB: involvement in addiction, deletion models and looking forward. Curr Neuropharmacol 5:202–212CrossRefPubMedPubMedCentralGoogle Scholar
  24. Misra K, Pandey SC (2006) The decreased cyclic-AMP dependent-protein kinase A function in the nucleus accumbens: a role in alcohol drinking but not in anxiety-like behaviors in rats. Neuropsychopharmacology 31:1406–1419CrossRefPubMedGoogle Scholar
  25. Moonat S, Starkman BG, Sakharkar A, Pandey SC (2010) Neuroscience of alcoholism: molecular and cellular mechanisms. Cell Mol Life Sci 67:73–88CrossRefPubMedGoogle Scholar
  26. Newton PM, Messing RO (2006) Intracellular signaling pathways that regulate behavioral responses to ethanol. Pharmacol Ther 109:227–237CrossRefPubMedGoogle Scholar
  27. Osterndorff-Kahanek E, Ponomarev I, Blednov YA, Harris RA (2013) Gene expression in brain and liver produced by three different regimens of alcohol consumption in mice: comparison with immune activation. PLoS One 8:e59870CrossRefPubMedPubMedCentralGoogle Scholar
  28. Pandey SC (2004) The gene transcription factor cyclic AMP-responsive element binding protein: role in positive and negative affective states of alcohol addiction. Pharmacol Therapeut 104:47–58CrossRefGoogle Scholar
  29. Pandey SC, Saito T, Yoshimura M, Sohma H, Gotz ME (2001) cAmp signaling cascade: a promising role in ethanol tolerance and dependence. Alcohol Clin Exp Res 25:46S–48SCrossRefPubMedGoogle Scholar
  30. Pandey SC, Roy A, Zhang H, Xu T (2004) Partial deletion of the cAMP response element-binding protein gene promotes alcohol-drinking behaviors. J Neurosci 24:5022–5030CrossRefPubMedGoogle Scholar
  31. Qiu X, Huang Y, Wu D, Mao F, Zhu J, Yan W, Luo HB, Li J (2018) Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: structure-based virtual screening, optimization and biological evaluation. Bioorg Med Chem 26:119–133CrossRefPubMedGoogle Scholar
  32. Romieu P, Gobaille S, Aunis D, Zwiller J (2008) Injection of the neuropeptide CNP into dopaminergic rat brain areas decreases alcohol intake. Ann N Y Acad Sci 1139:27–33CrossRefPubMedGoogle Scholar
  33. Saito T, Lee JM, Hoffman PL, Tabakoff B (1987) Effects of chronic ethanol treatment on the beta-adrenergic receptor-coupled adenylate cyclase system of mouse cerebral cortex. J Neurochem 48:1817–1822CrossRefPubMedGoogle Scholar
  34. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681–690CrossRefPubMedGoogle Scholar
  35. Spanagel R, Siegmund S, Cowen M, Schroff KC, Schumann G, Fiserova M, Sillaber I, Wellek S, Singer M, Putzke J (2002) The neuronal nitric oxide synthase gene is critically involved in neurobehavioral effects of alcohol. J Neurosci 22:8676–8683CrossRefPubMedGoogle Scholar
  36. Thiele TE, Willis B, Stadler J, Reynolds JG, Bernstein IL, McKnight GS (2000) High ethanol consumption and low sensitivity to ethanol-induced sedation in protein kinase A-mutant mice. J Neurosci 20:RC75CrossRefPubMedGoogle Scholar
  37. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J (2003) mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566–580CrossRefPubMedGoogle Scholar
  38. Wang L, Xiaokaiti Y, Wang G, Xu X, Chen L, Huang X, Liu L, Pan J, Hu S, Chen Z, Xu Y (2017) Inhibition of PDE2 reverses beta am dependent yloid induced memory impairment through regulation of PKA/PKG- neuro-inflammatory and apoptotic pathways. Sci Rep 7:12044CrossRefPubMedPubMedCentralGoogle Scholar
  39. Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, Zhang HT, Liang JH (2012) The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring fawn-hooded rats. Alcohol Clin Exp Res 36:2157–2167CrossRefPubMedPubMedCentralGoogle Scholar
  40. Wen RT, Feng WY, Liang JH, Zhang HT (2015) Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence. Curr Pharm Des 21:355–364CrossRefPubMedGoogle Scholar
  41. Wen RT, Zhang FF, Zhang HT (2018) Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder. Psychopharmacology 235(6):1793–1805CrossRefPubMedGoogle Scholar
  42. Werner C, Raivich G, Cowen M, Strekalova T, Sillaber I, Buters JT, Spanagel R, Hofmann F (2004) Importance of NO/cGMP signalling via cGMP-dependent protein kinase II for controlling emotionality and neurobehavioural effects of alcohol. Eur J Neurosci 20:3498–3506CrossRefPubMedGoogle Scholar
  43. Xu Y, Pan J, Chen L, Zhang C, Sun J, Li J, Nguyen L, Nair N, Zhang H, O'Donnell JM (2013) Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. Int J Neuropsychopharmacol 16:835–847CrossRefPubMedGoogle Scholar
  44. Xu Y, Pan J, Sun J, Ding L, Ruan L, Reed M, Yu X, Klabnik J, Lin D, Li J, Chen L, Zhang C, Zhang H, O'Donnell JM (2015) Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress. Neurobiol Aging 36:955–970CrossRefPubMedGoogle Scholar
  45. Yang X, Diehl AM, Wand GS (1996) Ethanol exposure alters the phosphorylation of cyclic AMP responsive element binding protein and cyclic AMP responsive element binding activity in rat cerebellum. J Pharmacol Exp Ther 278:338–346PubMedGoogle Scholar
  46. Yoneyama N, Crabbe JC, Ford MM, Murillo A, Finn DA (2008) Voluntary ethanol consumption in 22 inbred mouse strains. Alcohol 42:149–160CrossRefPubMedPubMedCentralGoogle Scholar
  47. Zhang HT, O'Donnell JM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology 150:311–316CrossRefPubMedGoogle Scholar
  48. Zhang C, Lueptow LM, Zhang HT, O'Donnell JM, Xu Y (2017) The role of phosphodiesterase-2 in psychiatric and neurodegenerative disorders. Adv Neurobiol 17:307–347CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jing Shi
    • 1
  • Huaxia Liu
    • 2
  • Jianchun Pan
    • 3
  • Jie Chen
    • 3
  • Nianping Zhang
    • 4
  • Kaiping Liu
    • 3
  • Ning Fei
    • 3
  • James M. O’Donnell
    • 5
  • Han-Ting Zhang
    • 6
    • 7
    Email author
  • Ying Xu
    • 5
    Email author
  1. 1.School of PharmacyHangzhou Medical CollegeHangzhouChina
  2. 2.School of NursingTaishan Medical UniversityTai’anChina
  3. 3.Brain InstituteWenzhou Medical University School of PharmacyWenzhouChina
  4. 4.Datong University Medical CollegeDatongChina
  5. 5.Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical SciencesUniversity at Buffalo, the State University of New YorkBuffaloUSA
  6. 6.Departments of Behavioral Medicine & Psychiatry and Physiology, Pharmacology & Neuroscience, Rockefeller Neurosciences InstituteWest Virginia University Health Sciences CenterMorgantownUSA
  7. 7.Institute of PharmacologyTaishan Medical UniversityTai’anChina

Personalised recommendations